Expression and significance of EGFR in malignant peripheral nerve sheath tumor

Journal of Neuro-Oncology

Volumn 94, Issue 3, 2009, Pages 383-388

  Keizman, Daniel ^a   Issakov, Josephine ^b   Meller, Isaac ^b   Meimon, Natalie ^a   Ish Shalom, Maya ^b   Sher, Osnat ^b   Merimsky, Ofer ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Epidermal growth factor receptor (EGFR); Malignant peripheral nerve sheath tumor (MPNST); Prognosis; Survival

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; IFOSFAMIDE;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE FUNCTION; GENE LOCATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MITOSIS RATE; NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; PRIMARY TUMOR; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME;

ADULT; COHORT STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NERVE SHEATH NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 69249240322     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-9862-z     Document Type: Article

References (34)

1. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM (1986) Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 57:2006-2021
2. Kar M, Deo SV, Shukla NK, Malik A, DattaGupta S, Mohanti BK, Thulkar S (2006) Malignant peripheral nerve sheath tumors (MPNST) - clinicopathological study and treatment outcome of twenty-four cases. World J Surg Oncol 4:55
3. Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, Lozza L, Collini P, Olmi P, Casali PG, Pilotti S, Gronchi A (2006) Malignant peripheral nerve sheath tumors: Prognostic factors and survival in a series of patients treated at a single institution. Cancer 107:1065-1074
4. Fuchs B, Spinner RJ, Rock MG (2005) Malignant peripheral nerve sheath tumors: An update. J Surg Orthop Adv 14:168-174
5. Gupta G, Maniker A (2007) Malignant peripheral nerve sheath tumors. Neurosurg Focus 22:E12
6. Spano JP, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R, Attar A, Benichou J, Martin A, Morere JF, Raphael M, Penault-Llorca F, Breau JL, Fagard R, Khayat D, Wind P (2005) Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 16:102-108
7. Baselga J, Arteaga CL (2005) Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23:2445-2459
8. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366:2-16
9. Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS (2007) Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 19:2013-2023
10. Yang JL, Hannan MT, Russell PJ, Crowe PJ (2006) Expression of HER1/EGFR protein in human soft tissue sarcomas. Eur J Surg Oncol 32:466-468
11. Harari PM, Allen GW, Bonner JA (2007) Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol 25:4057-4065
12. Ritter CA, Arteaga CL (2003) The epidermal growth factor receptor-tyrosine kinase: A promising therapeutic target in solid tumors. Semin Oncol 30:3-11
13. Yang JL, Crowe PJ (2007) Targeted therapies in adult soft tissue sarcomas. J Surg Oncol 95:183-184
14. Holtkamp N, Malzer E, Zietsch J, Okuducu AF, Mucha J, Mawrin C, Mautner V, Schildhaus HU, von Deimling A (2008) EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. Neuro-oncology 10(6):946-957. doi: 10.1215/15228517-2008-053
15. Perry A, Kunz SN, Fuller CE, Banerjee R, Marley EF, Liapis H, Watson MA, Gutmann DH (2002) Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. J Neuropathol Exp Neurol 61:702-709
16. Tabone-Eglinger S, Bahleda R, Cote JF, Terrier P, Vidaud D, Cayre A, Beauchet A, Theou-Anton N, Terrier-Lacombe MJ, Lemoine A, Penault-Llorca F, Le Cesne A, Emile JF (2008) Frequent EGFR positivity and overexpression in high-grade areas of human MPNSTs. Sarcoma 2008:849156
17. Watson MA, Perry A, Tihan T, Prayson RA, Guha A, Bridge J, Ferner R, Gutmann DH (2004) Gene expression profiling reveals unique molecular subtypes of Neurofibromatosis Type I-associated and sporadic malignant peripheral nerve sheath tumors. Brain Pathol 14:297-303
18. Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, Vilain MO, Mandard AM, Le Doussal V, Leroux A, Jacquemier J, Duplay H, Sastre-Garau X, Costa J (1997) Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 15:350-362
19. Greene FL, Page DL, Fleming ID et al (eds) (2002) AJCC cancer staging manual. Springer, New York
20. Brennan MF, Singer S, Maki RG, O'Sullivan B (2008) DeVita, Hellman, and Rosenberg's cancer: Principles & practice of oncology. In: DeVita VT Jr, Lawrence TS, Rosenberg SA (eds) Chapter 45: Sarcomas of the soft tissue and bone. Sect. 1: Soft tissue sarcoma. Wolters Kluwer, Amsterdam
21. Goldstein NS, Armin M (2001) Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: Implications for a standardized scoring system. Cancer 92:1331-1346
22. Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
23. Khalifa MA, Rowsell CH, Gladdy RA, Ko YJ, Hanna S, Smith A, Law C (2006) Expression of epidermal growth factor receptor in primary colorectal adenocarcinoma predicts expression in recurrent disease. Am J Clin Pathol 125:229-233
24. Tsutsui S, Ohno S, Murakami S, Kataoka A, Kinoshita J, Hachitanda Y (2002) Comparison of the immunohistochemical expression of EGFR, c-erbB2 and p53 protein between primary and recurrent breast cancer. Breast Cancer 9:111-117
25. Li H, Velasco-Miguel S, Vass WC, Parada LF, DeClue JE (2002) Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model. Cancer Res 62:4507-4513
26. Ling BC, Wu J, Miller SJ, Monk KR, Shamekh R, Rizvi TA, Decourten-Myers G, Vogel KS, DeClue JE, Ratner N (2005) Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. Cancer Cell 7:65-75
27. Sato O, Wada T, Kawai A, Yamaguchi U, Makimoto A, Kokai Y, Yamashita T, Chuman H, Beppu Y, Tani Y, Hasegawa T (2005) Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: A clinicopathologic study of 281 cases. Cancer 103:1881-1890
28. Kersting C, Packeisen J, Leidinger B, Brandt B, von Wasielewski R, Winkelmann W, van Diest PJ, Gosheger G, Buerger H (2006) Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas. J Clin Pathol 59:585-590
29. Tawbi H, Thomas D, Lucas DR, Biermann JS, Schuetze SM, Hart AL, Chugh R, Baker LH (2008) Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors. Oncologist 13:459-466
30. Tong WM, Ellinger A, Sheinin Y, Cross HS (1998) Epidermal growth factor receptor expression in primary cultured human colorectal carcinoma cells. Br J Cancer 77:1792-1798
31. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345
32. Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21:2787-2799
33. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208
34. Albritton KH, Rankin C, Coffin CM, Ratner N, Budd GT, Schuetze SM, Randall RL, Declue JE, Borden EC (2006) Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST). J Clin Oncol 2006 ASCO Ann Meet Proc I. 24:9518